[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614867":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":17,"locations":10,"responsibleParty":27,"collaborators":10,"id":31,"slug":10,"hasResults":32,"nctId":33,"briefTitle":9,"officialTitle":9,"acronym":10,"eligibilityCriteria":34,"healthyVolunteers":32,"sex":35,"minAge":36,"maxAge":10,"enrollmentInfo":37,"targetDuration":40,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":46,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Shanghai Lymphoma Clinical Cohort",null,[12],"Other: No interventions need to be specified for this study",[14],{"type":6,"name":15,"description":15,"armGroupLabels":16,"otherNames":10},"No interventions need to be specified for this study",[9],[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Weili Zhao, MD, PhD","CONTACT","+862164370045","Ext. 610707","zwl_trial@163.com",{"name":25,"role":20,"phone":21,"phoneExt":22,"email":26},"Pengpeng Xu, MD","pengpeng_xu@126.com",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhao Weili","Dean","100614867",false,"NCT07285174","Inclusion Criteria:\n\n1. Age ≥ 16 years (including 16 years old).\n2. Patients newly diagnosed with non-Hodgkin lymphoma\n3. Patients who have received systematic clinical treatment.\n4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.\n\nExclusion Criteria:\n\n1. Patients who only receive supportive treatment.\n2. Patients who cannot obtain effective evaluation data of efficacy.","ALL","16 Years",{"count":38,"type":39},1000,"ESTIMATED","2 Years","OBSERVATIONAL","The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.",[44,45],"Lymphoma","Cohort",[44,47,45],"Clinical","NOT_YET_RECRUITING","2025-12-03",{"date":51,"type":52},"2025-12-16","ACTUAL",{"date":54,"type":39},"2025-12-18",{"date":56,"type":39},"2029-12-31",{"name":5,"class":6}]